亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

医学 中止 不利影响 入射(几何) 耐受性 内科学 安慰剂 人口 肌酐 析因分析 危险系数 置信区间 病理 物理 替代医学 光学 环境卫生
作者
R. Scott Wright,Wolfgang Köenig,Ulf Landmesser,Lawrence A. Leiter,Frederick J. Raal,Gregory G. Schwartz,Anastasia Lesogor,Pierre Maheux,Christian Stratz,Xiao Zang,Kausik K. Ray
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:82 (24): 2251-2261 被引量:34
标识
DOI:10.1016/j.jacc.2023.10.007
摘要

Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol. The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran. This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Exposure-adjusted incidence rates and Kaplan-Meier estimates of cumulative incidence of reported treatment-emergent adverse events (TEAE), abnormal laboratory measurements, and incidence of antidrug antibodies were analyzed. This analysis included 3,576 patients treated with inclisiran for up to 6 years and 1,968 patients treated with placebo for up to 1.5 years, with 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. Kaplan-Meier analyses showed that TEAEs that were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs. Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
9秒前
19秒前
朴实云应发布了新的文献求助10
25秒前
林子青完成签到,获得积分10
59秒前
核桃发布了新的文献求助30
1分钟前
李健应助reerwt采纳,获得10
1分钟前
1分钟前
ICSSCI发布了新的文献求助10
1分钟前
1分钟前
刘宇童给刘宇童的求助进行了留言
1分钟前
reerwt发布了新的文献求助10
1分钟前
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
ICSSCI完成签到,获得积分10
2分钟前
2分钟前
董可以发布了新的文献求助10
2分钟前
风华正茂完成签到,获得积分10
2分钟前
2分钟前
3分钟前
jimmy_bytheway完成签到,获得积分0
3分钟前
桃桃发布了新的文献求助10
3分钟前
可爱的函函应助桃桃采纳,获得10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
NexusExplorer应助科研通管家采纳,获得10
3分钟前
所所应助爱笑的毛衣采纳,获得10
3分钟前
4分钟前
4分钟前
duan完成签到 ,获得积分10
4分钟前
holder完成签到,获得积分10
4分钟前
4分钟前
沐白发布了新的文献求助10
4分钟前
4分钟前
刘宇童发布了新的文献求助10
5分钟前
大模型应助吕易巧采纳,获得10
5分钟前
迷人问兰完成签到,获得积分10
5分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990049
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256369
捐赠科研通 3270998
什么是DOI,文献DOI怎么找? 1805166
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228